DERM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Journey Medical Corp (DERM) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has shown some positive pre-market movement and a favorable analyst rating, the lack of clear technical signals, weak trading trends, and absence of recent news or catalysts make it a hold rather than a buy. The investor should wait for stronger entry points or more compelling data.
The MACD histogram is negative and contracting (-0.0241), RSI is neutral at 54.831, and moving averages are converging, indicating no clear trend. Key support and resistance levels are Pivot: 6.144, R1: 6.385, S1: 5.903, R2: 6.533, S2: 5.755. Overall, the technical indicators suggest a neutral outlook.
Analyst B. Riley raised the price target to $12 from $11, maintaining a Buy rating. Strong Q4 execution and prescription volume growth of 50% sequentially provide a positive outlook.
No significant trading trends from hedge funds or insiders. No recent news or event-driven catalysts. Stock trend analysis shows a 50% chance of a -3.04% decline in the next day and a -6.05% decline in the next week.
No financial data available for analysis.
B. Riley maintains a Buy rating with a raised price target of $12, citing strong Q4 execution and growth in prescription volumes.
